140 related articles for article (PubMed ID: 37101355)
1. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer.
Yuan Y; Zhang S; Wang T; Bian L; Yan M; Yin Y; Song Y; Wen Y; Li J; Jiang Z
Chin Med J (Engl); 2023 Jun; 136(12):1459-1467. PubMed ID: 37101355
[TBL] [Abstract][Full Text] [Related]
2. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Corbaux P; Lardy-Cleaud A; Alexandre M; Fontanilles M; Lévy C; Viansone AA; Mailliez A; Debled M; Goncalves A; Le Du F; Lerebours F; Ferrero JM; Eymard JC; Mouret-Reynier MA; Petit T; Frenel JS; Dalenc F; Courtinard C; Chaix M; Bachelot T
Breast Cancer Res Treat; 2022 Jan; 191(1):191-207. PubMed ID: 34687411
[TBL] [Abstract][Full Text] [Related]
4. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
5. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Ha MJ; Singareeka Raghavendra A; Kettner NM; Qiao W; Damodaran S; Layman RM; Hunt KK; Shen Y; Tripathy D; Keyomarsi K
Int J Cancer; 2022 Jun; 150(12):2025-2037. PubMed ID: 35133007
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR
Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L
Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
11. Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Xie Y; Zhao Y; Gong C; Chen Z; Zhang Y; Zhao Y; Yuan P; Hu S; Li Y; Hu X; Zhang J; Wang L; Wang B
Sci Rep; 2019 Feb; 9(1):1710. PubMed ID: 30737426
[TBL] [Abstract][Full Text] [Related]
12. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
14. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.
Yuan Y; Zhang S; Yan M; Yin Y; Song Y; Jiang Z
Ann Transl Med; 2021 May; 9(10):831. PubMed ID: 34164465
[TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
[TBL] [Abstract][Full Text] [Related]
19. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]